Trial Profile

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 in Adult Participants With Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 986326 (Primary) ; BMS 986326 (Primary)
Indications Cutaneous lupus erythematosus; Discoid lupus erythematosus; Systemic lupus erythematosus
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

29 Jun 2025 Planned End Date changed from 24 Nov 2025 to 12 Apr 2026.
29 Jun 2025 Planned primary completion date changed from 24 Nov 2025 to 12 Apr 2026.
22 Feb 2024 Planned End Date changed from 18 Aug 2025 to 24 Nov 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com